Dosing

Summary of Product Characteristics

Important Safety Information

Dosing Schedule Simulator

SKYRIZI (risankizumab) is a selective IL-23/p19 inhibitor indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

.

I want to receive more information via a product specialist

Go

SUMMARY OF PRODUCT CHARACTERISTICS